The results of the 20-patients clinical study were published in the
Discrepancies between echocardiogram- and catheter-derived gradients have previously been reported by multiple groups after TAVR implantation, most likely due to inherent limitations of echocardiographic data acquisition, and other phenomena such as flow recovery after TAVR implantation.
These new clinical data presented by Dr. Philippe Généreux (
1) hemodynamic assessment derived from the OpSens OptoWire III and the new TAVR algorithm demonstrated excellent correlation with measurements derived from standard catheterization technique using two pigtails; and
2) compared with transthoracic echocardiogram and transesophageal echocardiographic, the OpSens OptoWire III demonstrated the strongest correlation with catheterization measurement.
"These data support the accuracy of the Fidela™ optical sensor when compared to the gold standard of invasive hemodynamics using two pigtail catheters," noted
The SavvyWire™ is a third-generation, intelligent and pre-shaped structural guidewire with integrated pressure monitoring and the capacity to perform left ventricular pacing. This device aims at improving procedural efficiency and clinical outcomes by allowing multiple steps over the same device without exchange, in line with the minimalist approach. The SavvyWire™ was recently approved by
Note:
The Fidela™ optical sensor embedded within the OptoWire III and the TAVR software algorithm integrated to the
Aortic valve stenosis occurs when the heart's aortic valve narrows, which prevents the valve from opening fully, restricting blood flow from the heart into the main artery (aorta) and onward to the rest of the body.
Initially, the TAVR procedure was only indicated for inoperable patients and then for high-risk surgical patients. Clinical programs like ''PARTNER III'' and ''Evolut Low Risk'', have since shown better or equivalent clinical outcomes in intermediate and low-risk patients. The TAVR procedure is now evolving quickly with a minimalist approach that allows the procedure to be faster and the patients to be discharged earlier, sometimes on the same day.
The TAVR procedure is on the rise, driven by an aging of the population and recent studies that demonstrate its benefits to patients in a broader range of conditions.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, and achievements of
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
SOURCE
© Canada Newswire, source